Preparation of naringenin/ β -cyclodextrin complex and its more potent alleviative effect on choroidal neovascularization in rats

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Xu, Xin Rong ^a   Yu, Hai Tao ^a   Hang, Li ^a   Shao, Yan ^a   Ding, Shu Hua ^a   Yang, Xue Wen ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN; CYCLOOXYGENASE 2; GELATINASE A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; NARINGENIN; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; BETA CYCLODEXTRIN DERIVATIVE; FLAVANONE DERIVATIVE; MATRIX METALLOPROTEINASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; INFRARED RADIATION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SUBRETINAL NEOVASCULARIZATION; X RAY DIFFRACTION; ANIMAL; CHEMISTRY; CHOROID; DRUG EFFECTS; GENETICS; INFRARED SPECTROPHOTOMETRY; METABOLISM; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BETA-CYCLODEXTRINS; CHOROID; CHOROIDAL NEOVASCULARIZATION; FLAVANONES; MALE; MATRIX METALLOPROTEINASES; RATS; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY, INFRARED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; X-RAY DIFFRACTION;

EID: 84899549001     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/623509     Document Type: Article

References (32)

1. Lu M., Adamis A. P., Molecular biology of choroidal neovascularization. Ophthalmology Clinics of North America 2006 19 3 323 334 2-s2.0-33748786807 10.1016/j.ohc.2006.05.001 (Pubitemid 44403942)
2. Miller D. G., Singerman L. J., Vision loss in younger patients: a review of choroidal neovascularization. Optometry and Vision Science 2006 83 5 316 325 2-s2.0-33744491282 10.1097/01.opx.0000216019.88256.eb (Pubitemid 43804571)
3. Ng E. W., Adamis A. P., Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Canadian Journal of Ophthalmology 2005 40 3 352 368 2-s2.0-21744446220 (Pubitemid 40942262)
4. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004 25 4 581 611 2-s2.0-4143136640 10.1210/er.2003-0027 (Pubitemid 39099316)
5. Gragoudas E. S., Adamis A. P., Cunningham E. T. Jr., Feinsod M., Guyer D. R., Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine 2004 351 27 2805 2816 2-s2.0-11144239923 10.1056/NEJMoa042760 (Pubitemid 40051904)
6. Michels S., Rosenfeld P. J., Puliafito C. A., Marcus E. N., Venkatraman A. S., Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005 112 6 1035 1047 2-s2.0-20144372969 10.1016/j.ophtha.2005.02.007 (Pubitemid 40797459)
7. Rosenfeld P. J., Moshfeghi A. A., Puliafito C. A., Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging 2005 36 4 331 335 2-s2.0-23044505200 (Pubitemid 41073112)
8. 3-induced retinal pigment epithelium degeneration and laser-induced choroidal neovascularization in rats. International Journal of Ophthalmology 2010 3 1 5 8 2-s2.0-76149087474 10.3980/j.issn.2222-3959.2010.01.02
9. Uekama K., Design and evaluation of cyclodextrin-based drug formulation. Chemical and Pharmaceutical Bulletin 2004 52 8 900 915 2-s2.0-16344364096 10.1248/cpb.52.900 (Pubitemid 41701863)
10. Moya-Ortega M. D., Alvarez-Lorenzo C., Concheiro A., Loftsson T., Cyclodextrin-based nanogels for pharmaceutical and biomedical applications. International Journal of Pharmaceutics 2012 428 1-2 152 163 2-s2.0-84859428717 10.1016/j.ijpharm.2012.02.038
11. Luke D. R., Tomaszewski K., Damle B., Schlamm H. T., Review of the basic and clinical pharmacology of sulfobutylether- β-cyclodextrin (SBECD). Journal of Pharmaceutical Sciences 2010 99 8 3291 3301 2-s2.0-77955154715 10.1002/jps.22109
12. Singh S. R., Grossniklaus H. E., Kang S. J., Edelhauser H. F., Ambati B. K., Kompella U. B., Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Therapy 2009 16 5 645 659 2-s2.0-67349119829 10.1038/gt.2008.185
13. Fu Y., Zheng S., Lin J., Ryerse J., Chen A., Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Molecular Pharmacology 2008 73 2 399 409 2-s2.0-38549153486 10.1124/mol.107.039818 (Pubitemid 351159210)
14. Schmittgen T. D., Zakrajsek B. A., Mills A. G., Gorn V., Singer M. J., Reed M. W., Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Analytical Biochemistry 2000 285 2 194 204 2-s2.0-0034668118 10.1006/abio.2000.4753
15. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Archives of Ophthalmology 1991 109 9 1242 1257 10.1001/archopht.1991.01080090066027 2-s2.0-0025776268
16. Caputo M., Zirpoli H., di Benedetto R., de Nadai K., Tecce M. F., Perspectives of choroidal neovascularization therapy. Current Drug Targets 2011 12 2 234 242 2-s2.0-79955670905
17. Wang J., Yang Z., Lin L., Zhao Z., Liu Z., Liu X., Protective effect of naringenin against lead-induced oxidative stress in rats. Biological Trace Element Research 2012 146 3 354 359 2-s2.0-81555230002 10.1007/s12011-011-9268-6
18. Ji J., Xu X., Chiou C. Y., Effects of naringenin on ocular blood flow and choroidal neovascularization in experimental animals. International Journal of Ophthalmology 2009 2 4 320 323 2-s2.0-59849124845
19. Schreiber S. L., Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000 287 5460 1964 1969 2-s2.0-0034678033 10.1126/science.287.5460.1964 (Pubitemid 30158663)
20. Purkayastha P., Jaffer S. S., Ghosh P., Physicochemical perspective of cyclodextrin nano and microaggregates. Physical Chemistry Chemical Physics 2012 14 16 5339 5348 2-s2.0-84859328261 10.1039/c2cp24052a
21. Zhang Y., Cui Y., Influence of 2-hydroxypropyl- β -cyclodextrin complexation on P-glycoprotein drug pump in the intestine of rats. Chinese Pharmacological Bulletin 2008 24 10 1318 1323 2-s2.0-58149202367
22. Shulman M., Cohen M., Soto-Gutierrez A., Yagi H., Wang H., Goldwasser J., Lee-Parsons C. W., Benny-Ratsaby O., Yarmush M. L., Nahmias Y., Enhancement of naringenin bioavailability by complexation with hydroxypropoyl- β -cyclodextrin. PLoS ONE 2011 6 4 2-s2.0-79953748950 10.1371/journal.pone.0018033 e18033
23. Bok D., Evidence for an inflammatory process in age-related macular degeneration gains new support. Proceedings of the National Academy of Sciences of the United States of America 2005 102 20 7053 7054 2-s2.0-18844453162 10.1073/pnas.0502819102 (Pubitemid 40696331)
24. Castro M. R., Lutz D., Edelman J. L., Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Experimental Eye Research 2004 79 2 275 285 2-s2.0-4344663889 10.1016/j.exer.2004.04.008 (Pubitemid 39119416)
25. Kuwano T., Nakao S., Yamamoto H., Tsuneyoshi M., Yamamoto T., Kuwano M., Ono M., Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. The FASEB Journal 2004 18 2 300 310 2-s2.0-0442277878 10.1096/fj.03-0473com (Pubitemid 38186249)
26. Larkins T. L., Nowell M., Singh S., Sanford G. L., Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006 6, article 181 2-s2.0-33748358343 10.1186/1471-2407-6-181 (Pubitemid 44335961)
27. Costa C., Hirsch E., More than just kinases: the scaffolding function of PI3K. Current Topics in Microbiology and Immunology 2011 346 171 181 10.1007/82-2010-57 2-s2.0-79952112577
28. Huang P., Han J., Hui L., MAPK signaling in inflammation-associated cancer development. Protein & Cell 2010 1 3 218 226 2-s2.0-79953163484 10.1007/s13238-010-0019-9
29. Colleselli D., Bijuklic K., Mosheimer B. A., Kähler C. M., Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. Experimental Cell Research 2006 312 15 2933 2941 2-s2.0-33747377104 10.1016/j.yexcr.2006.05.021
30. Yong H. Y., Koh M. S., Moon A., The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs 2009 18 12 1893 1905 2-s2.0-72249120832 10.1517/13543780903321490
31. 2 by endothelin-1 via MAPK-dependent NF- B pathway in mouse brain microvascular endothelial cells. Cell Communication and Signaling 2013 11 1, article 8 10.1186/1478-811X-11-8
32. 2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. Journal of Biological Chemistry 1998 273 44 28670 28676 2-s2.0-0032582347 10.1074/jbc.273.44.28670 (Pubitemid 28507552)